+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Granulocyte Macrophage Colony Stimulating Factor Market by Product (Biosimilar, Recombinant), Application (Acute Myeloid Leukemia, Chemotherapy Induced Neutropenia, Chronic Myelogenous Leukemia), Route, End User, Dosage Form, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6137213
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) has emerged as a pivotal biologic in the modulation of innate immune responses, harnessing the capability to accelerate the proliferation and differentiation of myeloid lineage cells. This glycoprotein cytokine orchestrates a complex interplay between hematopoietic progenitors and mature leukocytes, thereby fortifying the body’s defense against infections and promoting recovery following myelosuppressive treatments.

Over the past decade, advances in protein engineering and recombinant DNA technology have propelled GM-CSF from bench to bedside, leading to a new generation of therapeutics that offer improved stability and enhanced receptor affinity. Regulatory milestones across key jurisdictions have validated these innovations, underpinning the clinical confidence in both recombinant and biosimilar alternatives poised to improve patient access and affordability.

Within the context of personalized medicine, biomarker-driven patient stratification is redefining therapeutic pathways for GM-CSF, enabling clinicians to tailor dosing regimens and anticipate adverse events with greater precision. Stakeholders from pharmaceutical developers to contract manufacturing organizations are aligning efforts to streamline supply chains, ensuring that quality by design and robust process controls meet stringent regulatory standards. As the stage is set for further breakthroughs, this introduction lays the groundwork for understanding transformative shifts, tariff impacts, segmentation insights, regional dynamics, and strategic imperatives that will collectively shape the GM-CSF ecosystem in the years to come

Unveiling the Transformative Shifts in Biologic Development Supply Chains Regulatory Frameworks and Competitive Dynamics for GM-CSF

The GM-CSF landscape has undergone a series of profound transformations driven by technological advancements in cell culture systems, single-use bioreactors, and continuous processing methods. Enhanced process analytics and real-time monitoring have reduced batch variability, accelerating time to clinic and bolstering product consistency. At the same time, the maturation of quality by design principles has mandated deeper process understanding, ensuring that safety and efficacy parameters are met with unprecedented rigor across development pipelines.

Regulatory bodies worldwide have responded to these innovations with adaptive frameworks, introducing expedited pathways for biosimilars while reinforcing guidelines for immunogenicity assessment and post-marketing surveillance. This regulatory evolution has fueled healthy competition, prompting established players and emerging biotech ventures to invest in next-generation GM-CSF analogues and delivery platforms. Moreover, partnerships have proliferated between contract development and manufacturing organizations and innovators aiming to scale up capacity and diversify geographic footprints.

These developments have not only compressed development timelines but also reshaped competitive landscapes, challenging legacy pricing models and opening up new markets. As stakeholders embrace a more collaborative ethos, alliances spanning small biotechs, academic institutions, and multinational pharmaceutical firms are catalyzing translational research. By aligning scientific breakthroughs with strategic alliances, the industry is poised to deliver more efficacious and accessible treatments to patients worldwide

Assessing the Comprehensive Ramifications of 2025 United States Tariff Policies on Biologic Components Supply Chains and Commercial Strategies

The introduction of new tariff measures in 2025 has prompted a comprehensive reassessment of supply chain structures for GM-CSF raw materials and ancillary components. Imported culture media, filters, and single-use assemblies have become subject to increased duties, driving sourcing teams to reevaluate international partnerships and negotiate revised contracts. This shift has magnified the emphasis on backward integration, as manufacturers seek to secure domestic production of critical inputs to mitigate exposure to escalating costs.

Consequently, companies are exploring strategic alliances with local suppliers and investing in regional production hubs to reduce reliance on cross-border logistics. The readjustment of cost structures has also influenced pricing strategies, compelling stakeholders to balance margin preservation with affordability for healthcare providers. At the same time, distributors have reevaluated inventory models to account for potential lead-time fluctuations, enhancing buffer stocks and collaborating more closely with logistics partners to sustain consistent supply flows.

Despite these challenges, the tariffs have accelerated conversations around reshoring and nearshoring, galvanizing policymakers to incentivize biotech infrastructure development. Public-private initiatives are facilitating grants and tax credits for domestic bioprocessing facilities, fostering resilience across the GM-CSF value chain. In this evolving environment, forward-thinking organizations are leveraging scenario planning and dynamic costing tools to navigate tariff uncertainties while safeguarding patient access and sustaining long-term growth

Illuminating Key Market Segmentation Dimensions to Decipher Diverse Product Applications and Delivery Modalities for GM-CSF

The GM-CSF portfolio comprises both biosimilar and recombinant products, each at various stages of approval and development. Biosimilars have progressed through rigorous comparability exercises and are either approved or actively advancing through clinical trials, while recombinant analogues similarly traverse pathways to secure market authorization. Variations in molecular structure and manufacturing processes underpin these distinctions, influencing competitive positioning and cost differentials.

On the application front, GM-CSF therapies address a spectrum of hematologic and oncologic indications. Approved regimens for Acute Myeloid Leukemia are complemented by development-stage protocols, and the landscape of chemotherapy-induced neutropenia includes both established and investigational formulations. Chronic Myelogenous Leukemia represents another avenue of research, with candidates at different clinical milestones refining dosing schemas and safety profiles to enhance patient outcomes.

Delivery mode segmentation further informs strategic planning, with intravenous administration dominating acute care settings, while subcutaneous formulations optimize outpatient and home care experiences. End users range from home care services to large hospital systems, research institutions, and specialized clinics, each with unique procurement dynamics and service models. Therapeutic formats encompass liquid solutions and lyophilized powders, both in approved and pipeline iterations, and distribution channels span hospital pharmacies, online platforms, and traditional retail outlets. This multifaceted segmentation framework enables stakeholders to tailor product offerings, align investment priorities, and address patient and provider needs across diverse care settings

Elucidating Regional Nuances Across Americas Europe Middle East Africa and Asia Pacific to Uncover Strategic Opportunities

In the Americas, mature healthcare ecosystems and established reimbursement infrastructures have facilitated early adoption of advanced GM-CSF therapies. North American jurisdictions benefit from streamlined regulatory alignment and robust clinical trial networks, while Latin American markets are experiencing gradual uptake driven by biosimilar affordability and public health initiatives aimed at improving cancer care access.

Europe, the Middle East, and Africa present a heterogeneous regulatory panorama, where harmonized standards coexist with localized pricing and reimbursement challenges. Western European nations have embraced biosimilar competition to contain costs, whereas emerging economies in the region are nurturing local manufacturing capacities through targeted incentives. In Middle Eastern and African markets, strategic partnerships and government-led procurement programs are instrumental in expanding access to hematopoietic Support therapies.

Asia-Pacific dynamics are characterized by rapid expansion in oncology incidence and increasing healthcare expenditure. Countries across this region are investing in biotechnology clusters and research collaborations to enhance domestic production capabilities. Meanwhile, policymakers in key markets are revising regulatory frameworks to accelerate approvals and incentivize innovation. Together, these regional nuances define the pathways through which GM-CSF therapies are adopted and scaled across global markets

Profiling Prominent Industry Participants Their Strategic Collaborations Pipeline Initiatives and Competitive Positioning in the GM-CSF Arena

Leading biopharmaceutical companies have strategically positioned themselves in the GM-CSF domain through a combination of in-house innovation and collaborative partnerships. Major innovators have leveraged their expertise in biologics to advance next-generation analogues, while biosimilar specialists continue to refine comparability packages and negotiate market access agreements. Contract development and manufacturing organizations remain integral, offering scale-up capabilities and flexible production platforms that support both innovators and emerging biotech entities.

Pipeline activity is increasingly oriented toward novel formulations, including pegylated variants and fusion proteins designed to extend half-life and improve dosing convenience. Strategic collaborations between established pharmaceutical firms and academic research centers are accelerating translational studies, while alliances with digital health providers are exploring real-time adherence monitoring and patient support solutions. These multifaceted partnerships underscore a competitive landscape shaped by both scientific ingenuity and operational agility.

Furthermore, cross-border mergers and acquisitions have reshuffled the competitive order, as large players acquire specialty biotech assets to bolster their hematopoietic portfolios. At the same time, niche developers continue to attract venture capital by targeting underserved indications and leveraging advanced drug delivery technologies. This dynamic interplay between scale and specialization is a hallmark of the current competitive environment in the GM-CSF arena

Defining Actionable Recommendations to Drive Sustainable Growth Enhance Accessibility and Strengthen Competitive Positioning in the GM-CSF Market

Industry leaders should prioritize investment in flexible manufacturing platforms that accommodate both recombinant and biosimilar production, enabling rapid scale-up in response to shifting demand patterns and tariff uncertainties. By deploying modular, single-use bioprocessing systems and diversifying supplier networks, organizations can enhance resilience and maintain competitive cost structures.

Engaging proactively with regulatory agencies through early scientific advice and adaptive licensing pathways will streamline approval processes for novel GM-CSF variants. Establishing clear communication channels and participating in policy discussions can secure expedited reviews and favorable reimbursement decisions, particularly for formulations that demonstrate clinical or economic advantages.

To address evolving patient needs and provider preferences, differentiating through formulation innovation and patient support services is critical. Developing long-acting or patient-administered delivery options, coupled with robust adherence and educational programs, will strengthen brand loyalty and drive market penetration in both hospital and home care settings.

Finally, forging cross-sector alliances with digital health, contract manufacturers, and regional distribution partners will unlock synergies in data analytics, supply chain optimization, and market access. Such collaborations will not only accelerate time to market but also create holistic care solutions that elevate outcomes for patients requiring hematopoietic support

Detailing a Rigorous Multi source Research Methodology Emphasizing Data Triangulation Expert Interviews and Comprehensive Secondary Analysis

This research integrates a comprehensive secondary analysis of peer-reviewed literature, regulatory filings, clinical trial registries, and public company disclosures to establish a foundational understanding of the GM-CSF landscape. Supplementary data from industry white papers and patent databases were scrutinized to capture emerging technologies, competitive pipelines, and intellectual property trends.

Primary insights were obtained through in-depth interviews with key opinion leaders, including hematologists, bioprocess engineers, and market access specialists, who provided nuanced perspectives on clinical adoption challenges and supply chain vulnerabilities. These discussions were complemented by consultations with manufacturing leaders and regulatory experts to validate assumptions around process optimization and tariff impacts.

Quantitative data was triangulated across multiple sources, ensuring consistency and reliability. Analytical frameworks such as SWOT and Porter’s Five Forces were employed to evaluate competitive intensity and market attractiveness. Regional adoption patterns and segmentation nuances were mapped using an iterative approach, facilitating a clear depiction of opportunity landscapes across geographies and therapeutic niches

Synthesizing Critical Conclusions to Illuminate Future Trajectories Risks and Opportunities within the GM-CSF Therapeutic Landscape

The current trajectory of GM-CSF therapeutics reflects an intricate tapestry of scientific innovation, regulatory adaptation, and market dynamics. Technological advancements in manufacturing and adaptive regulatory pathways have lowered barriers to entry, while emerging tariff measures have reshaped supply chain strategies. Together, these forces have redefined how organizations approach development, pricing, and distribution.

Segmentation insights reveal a diversified landscape in which product types, clinical applications, delivery modes, and end-user channels each present distinct value propositions and challenges. Regional nuances further underscore the necessity for tailored market access and partnership strategies, as stakeholders navigate the varied regulatory and economic contexts of the Americas, EMEA, and Asia-Pacific.

Collectively, the evolving competitive environment, characterized by strategic collaborations and pipeline diversification, highlights the importance of agility and foresight. By synthesizing these critical elements, industry leaders can identify high-impact opportunities, mitigate risks associated with tariff fluctuations, and align innovation efforts with unmet patient needs, ensuring sustained growth and improved healthcare outcomes in the GM-CSF domain

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product
    • Biosimilar
      • Approved
      • In Development
    • Recombinant
      • Approved
      • In Development
  • Application
    • Acute Myeloid Leukemia
      • Approved
      • In Development
    • Chemotherapy Induced Neutropenia
      • Approved
      • In Development
    • Chronic Myelogenous Leukemia
      • Approved
      • In Development
  • Route
    • Intravenous
    • Subcutaneous
  • End User
    • Home Care Settings
    • Hospitals
    • Research Institutions
    • Specialty Clinics
  • Dosage Form
    • Liquid Solution
      • Approved
      • In Development
    • Lyophilized Powder
      • Approved
      • In Development
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Partner Therapeutics, Inc.
  • Teva Pharmaceuticals Europe B.V.
  • Ferring Pharmaceuticals S.A.
  • Zenyaku Kogyo Co., Ltd.
  • Samyang Biopharm Co., Ltd.
  • Landos Biopharma, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emerging biosimilar GM-CSF products reshaping cost dynamics and market access for supportive oncology care
5.2. Increasing off-label use of GM-CSF in COVID-19 and viral pneumonia management influencing research pipelines
5.3. Advancements in single-use bioreactor technology intensifying GM-CSF manufacturing efficiency and scalability
5.4. Strategic licensing agreements between biotech firms expanding regional GM-CSF distribution in Asia-Pacific markets
5.5. Development of inhaled GM-CSF therapies unlocking novel treatment pathways for pulmonary alveolar proteinosis
5.6. Integration of GM-CSF with immuno-oncology regimens to enhance tumor microenvironment modulation
5.7. Patent expirations opening competitive landscape for next-generation GM-CSF formulations and combination drugs
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Granulocyte Macrophage Colony Stimulating Factor Market, by Product
8.1. Introduction
8.2. Biosimilar
8.2.1. Approved
8.2.2. In Development
8.3. Recombinant
8.3.1. Approved
8.3.2. In Development
9. Granulocyte Macrophage Colony Stimulating Factor Market, by Application
9.1. Introduction
9.2. Acute Myeloid Leukemia
9.2.1. Approved
9.2.2. In Development
9.3. Chemotherapy Induced Neutropenia
9.3.1. Approved
9.3.2. In Development
9.4. Chronic Myelogenous Leukemia
9.4.1. Approved
9.4.2. In Development
10. Granulocyte Macrophage Colony Stimulating Factor Market, by Route
10.1. Introduction
10.2. Intravenous
10.3. Subcutaneous
11. Granulocyte Macrophage Colony Stimulating Factor Market, by End User
11.1. Introduction
11.2. Home Care Settings
11.3. Hospitals
11.4. Research Institutions
11.5. Specialty Clinics
12. Granulocyte Macrophage Colony Stimulating Factor Market, by Dosage Form
12.1. Introduction
12.2. Liquid Solution
12.2.1. Approved
12.2.2. In Development
12.3. Lyophilized Powder
12.3.1. Approved
12.3.2. In Development
13. Granulocyte Macrophage Colony Stimulating Factor Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Americas Granulocyte Macrophage Colony Stimulating Factor Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Granulocyte Macrophage Colony Stimulating Factor Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Granulocyte Macrophage Colony Stimulating Factor Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Partner Therapeutics, Inc.
17.3.2. Teva Pharmaceuticals Europe B.V.
17.3.3. Ferring Pharmaceuticals S.A.
17.3.4. Zenyaku Kogyo Co., Ltd.
17.3.5. Samyang Biopharm Co., Ltd.
17.3.6. Landos Biopharma, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET: RESEARCHAI
FIGURE 28. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET: RESEARCHSTATISTICS
FIGURE 29. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET: RESEARCHCONTACTS
FIGURE 30. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPROVED, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY IN DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 151. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 152. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 153. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 154. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 155. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 156. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 157. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 158. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 159. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 160. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 161. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 162. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 163. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 164. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 165. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 166. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 167. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 172. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 173. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 174. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 175. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. CANADA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 178. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 179. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 180. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 181. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 182. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 183. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 184. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 185. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 186. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 187. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 188. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 189. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 190. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 191. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 192. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 193. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 196. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 197. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 199. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 200. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 201. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. MEXICO GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY RECOMBINANT, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHEMOTHERAPY INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY CHRONIC MYELOGENOUS LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY ROUTE, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LIQUID SOLUTION, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY LYOPHILIZED POWDER, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR MARKET SIZE, BY BIOSIMILAR, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AF

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Granulocyte Macrophage Colony Stimulating Factor market report include:
  • Partner Therapeutics, Inc.
  • Teva Pharmaceuticals Europe B.V.
  • Ferring Pharmaceuticals S.A.
  • Zenyaku Kogyo Co., Ltd.
  • Samyang Biopharm Co., Ltd.
  • Landos Biopharma, Inc.